TY - JOUR
T1 - Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders
T2 - improvement in signs and symptoms of atopic dermatitis and quality of life
AU - Blauvelt, Andrew
AU - Boguniewicz, Mark
AU - Brunner, Patrick M.
AU - Luna, Paula C.
AU - Biswas, Pinaki
AU - DiBonaventura, Marco
AU - Farooqui, Saleem A.
AU - Rojo, Ricardo
AU - Cameron, Michael C.
N1 - Publisher Copyright:
© 2022 Pfizer Inc. Published with license by Taylor & Francis Group, LLC.
PY - 2022
Y1 - 2022
N2 - Background: Abrocitinib, a once-daily, oral Janus kinase 1 selective inhibitor, was shown to be an effective treatment for moderate-to-severe atopic dermatitis in phase 2 b/3 monotherapy trials. Methods: These analyses included data for Investigator’s Global Assessment responder (clear [0] or almost clear [1] with ≥2-grade improvement) and nonresponder patients with moderate-to-severe atopic dermatitis who received abrocitinib (200 mg or 100 mg) or placebo in three abrocitinib monotherapy trials (phase 2 b, NCT02780167; two phase 3, NCT03349060/JADE MONO-1 and NCT03575871/JADE MONO-2). Outcomes measuring skin clearance, itch, and quality of life were evaluated. Results: Both nonresponders (n = 548) and responders (n = 260) treated with abrocitinib had rapid and clinically meaningful improvement in skin clearance, itch, and quality of life compared with placebo. Conclusion: Patients with moderate-to-severe atopic dermatitis treated with abrocitinib who did not achieve an Investigator’s Global Assessment 0/1 response at week 12 still experienced rapid, clinically meaningful improvements across several other validated measures of efficacy and quality of life. ClinicalTrials.gov: NCT02780167, NCT03349060, NCT03575871.
AB - Background: Abrocitinib, a once-daily, oral Janus kinase 1 selective inhibitor, was shown to be an effective treatment for moderate-to-severe atopic dermatitis in phase 2 b/3 monotherapy trials. Methods: These analyses included data for Investigator’s Global Assessment responder (clear [0] or almost clear [1] with ≥2-grade improvement) and nonresponder patients with moderate-to-severe atopic dermatitis who received abrocitinib (200 mg or 100 mg) or placebo in three abrocitinib monotherapy trials (phase 2 b, NCT02780167; two phase 3, NCT03349060/JADE MONO-1 and NCT03575871/JADE MONO-2). Outcomes measuring skin clearance, itch, and quality of life were evaluated. Results: Both nonresponders (n = 548) and responders (n = 260) treated with abrocitinib had rapid and clinically meaningful improvement in skin clearance, itch, and quality of life compared with placebo. Conclusion: Patients with moderate-to-severe atopic dermatitis treated with abrocitinib who did not achieve an Investigator’s Global Assessment 0/1 response at week 12 still experienced rapid, clinically meaningful improvements across several other validated measures of efficacy and quality of life. ClinicalTrials.gov: NCT02780167, NCT03349060, NCT03575871.
KW - Atopic dermatitis
KW - eczema
KW - pruritus
KW - quality of life
UR - http://www.scopus.com/inward/record.url?scp=85133526141&partnerID=8YFLogxK
U2 - 10.1080/09546634.2022.2059053
DO - 10.1080/09546634.2022.2059053
M3 - Article
C2 - 35763326
AN - SCOPUS:85133526141
SN - 0954-6634
VL - 33
SP - 2605
EP - 2613
JO - Journal of Dermatological Treatment
JF - Journal of Dermatological Treatment
IS - 5
ER -